Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

Blombery P, Birkinshaw RW, Nguyen T, Gong JN, Thompson ER, Xu Z, Westerman DA, Czabotar PE, Dickinson M, Huang DCS, Seymour JF, Roberts AW.

Br J Haematol. 2019 Jun 24. doi: 10.1111/bjh.16069. [Epub ahead of print] No abstract available.

PMID:
31234236
2.

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.

Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T, Tiong IS, Blombery P, Hofman MS, Westerman D, Hicks RJ, Kong G.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910. doi: 10.1007/s00259-019-04389-2. Epub 2019 Jun 11.

PMID:
31187162
3.

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

Birkinshaw RW, Gong JN, Luo CS, Lio D, White CA, Anderson MA, Blombery P, Lessene G, Majewski IJ, Thijssen R, Roberts AW, Huang DCS, Colman PM, Czabotar PE.

Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.

4.

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.

Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, Lim J, Soong J, Link E, Blombery P, Thompson ER, Fellowes A, Sheppard KE, McArthur GA, Pearson RB, Hannan RD, Poortinga G, Harrison SJ.

Cancer Discov. 2019 May 15. doi: 10.1158/2159-8290.CD-18-1455. [Epub ahead of print]

PMID:
31092402
5.

CNspector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing.

Markham JF, Yerneni S, Ryland GL, Leong HS, Fellowes A, Thompson ER, De Silva W, Kumar A, Lupat R, Li J, Ellul J, Fox S, Dickinson M, Papenfuss AT, Blombery P.

Sci Rep. 2019 Apr 23;9(1):6426. doi: 10.1038/s41598-019-42858-8.

6.

Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Blombery P, Thompson ER, Prince HM.

Plast Reconstr Surg. 2019 Mar;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):59S-64S. doi: 10.1097/PRS.0000000000005570. Review.

PMID:
30817557
7.

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma.

Blombery P, Thompson E, Ryland GL, Joyce R, Byrne DJ, Khoo C, Lade S, Hertzberg M, Hapgood G, Marlton P, Deva A, Lindeman G, Fox S, Westerman D, Prince M.

Oncotarget. 2018 Nov 16;9(90):36126-36136. doi: 10.18632/oncotarget.26308. eCollection 2018 Nov 16.

8.

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.

Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF.

Haematologica. 2019 Apr;104(4):700-709. doi: 10.3324/haematol.2018.201152. Epub 2018 Dec 13.

9.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.

PMID:
30514704
10.

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ.

Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19.

PMID:
30455436
11.

What does good FISHing look like in MDS?

Wall M, Blombery P.

Leuk Lymphoma. 2019 Mar;60(3):571-572. doi: 10.1080/10428194.2018.1529312. Epub 2018 Nov 8. No abstract available.

PMID:
30407101
12.

Revisiting acquired aplastic anaemia: current concepts in diagnosis and management.

Clucas DB, Fox LC, Wood EM, Hong FS, Gibson J, Bajel A, Szer J, Blombery P, McQuilten ZK, Hiwase D, Firkin F, Cole-Sinclair MF; Australian Aplastic Anaemia Registry Steering Committee.

Intern Med J. 2019 Feb;49(2):152-159. doi: 10.1111/imj.14140. Review.

PMID:
30324755
13.

"Reversible" myelodysplastic syndrome or ineffectual clonal haematopoiesis? - add(6p) myeloid neoplasm with a spontaneous cytogenetic remission.

Rady K, Blombery P, Westerman DA, Wall M, Curtis M, Campbell LJ, Seymour JF.

Leuk Res. 2018 Oct;73:1-4. doi: 10.1016/j.leukres.2018.08.010. Epub 2018 Aug 16.

PMID:
30170269
14.

Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapy.

Blombery P, Dawson SJ.

Leuk Lymphoma. 2019 Feb;60(2):279-280. doi: 10.1080/10428194.2018.1485916. Epub 2018 Aug 20. No abstract available.

PMID:
30124370
15.

Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.

Ryland GL, Jones K, Chin M, Markham J, Aydogan E, Kankanige Y, Caruso M, Guinto J, Dickinson M, Prince HM, Yong K, Blombery P.

J Clin Pathol. 2018 Oct;71(10):895-899. doi: 10.1136/jclinpath-2018-205195. Epub 2018 May 14.

PMID:
29760015
16.

Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.

Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD.

Intern Med J. 2018 Jun;48(6):624-636. doi: 10.1111/imj.13804. Review.

PMID:
29582550
17.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.

Mastaglio S, Wong E, Perera T, Ripley J, Blombery P, Smyth MJ, Koldej R, Ritchie D.

Blood Adv. 2018 Feb 27;2(4):335-346. doi: 10.1182/bloodadvances.2017015230.

18.

Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.

Blombery P, Jones K, Doig K, Ryland G, McBean M, Thompson E, Yannakou CK, Westerman D.

Arch Pathol Lab Med. 2018 May;142(5):606-612. doi: 10.5858/arpa.2017-0229-OA. Epub 2018 Feb 9.

PMID:
29425073
19.

Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.

Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD.

Nephrology (Carlton). 2018 Jun;23(6):507-517. doi: 10.1111/nep.13234. Review.

PMID:
29419916
20.

Canary: an atomic pipeline for clinical amplicon assays.

Doig KD, Ellul J, Fellowes A, Thompson ER, Ryland G, Blombery P, Papenfuss AT, Fox SB.

BMC Bioinformatics. 2017 Dec 15;18(1):555. doi: 10.1186/s12859-017-1950-z.

21.

ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach.

Yannakou CK, Jones K, McBean M, Thompson ER, Ryland GL, Doig K, Markham J, Westerman D, Blombery P.

Blood Cancer J. 2017 Dec 15;7(12):656. doi: 10.1038/s41408-017-0025-8. No abstract available.

22.

Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome.

Opat S, Hearps AC, Thia K, Yuen A, Rogers B, Chachage M, Moore G, Shortt J, Ryland G, Blombery P, Schwarer AP, Noori T, Trapani JA, Jaworowski A, Voskoboinik I.

Blood. 2018 Feb 8;131(6):699-702. doi: 10.1182/blood-2017-08-803668. Epub 2017 Dec 12. No abstract available.

23.

The price of success-health economics of personalized diffuse large B-cell lymphoma treatment.

Blombery P, Lickiss J, Dickinson M.

Leuk Lymphoma. 2018 Jul;59(7):1517-1519. doi: 10.1080/10428194.2017.1408088. Epub 2017 Dec 7. No abstract available.

PMID:
29214866
24.

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.

Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL.

Blood Cancer J. 2017 Sep 15;7(9):e610. doi: 10.1038/bcj.2017.76. No abstract available.

25.

Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour DNA using a single hybridisation-based next generation sequencing assay.

Blombery PA, Ryland GL, Markham J, Guinto J, Wall M, McBean M, Jones K, Thompson ER, Cameron DL, Papenfuss AT, Prince MH, Dickinson M, Westerman DA.

Br J Haematol. 2018 Oct;183(1):146-149. doi: 10.1111/bjh.14919. Epub 2017 Sep 7. No abstract available.

PMID:
28880377
26.

Incidental detection of germline variants of potential clinical significance by massively parallel sequencing in haematological malignancies.

Yannakou CK, Jones K, Ryland GL, Thompson ER, Reid G, McBean M, Trainer A, Westerman D, Blombery P.

J Clin Pathol. 2018 Jan;71(1):84-87. doi: 10.1136/jclinpath-2017-204481. Epub 2017 Aug 11.

PMID:
28801348
27.

Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry.

Ryland GL, Jones K, McBean M, Khot A, Seymour JF, Blombery P.

Leuk Lymphoma. 2018 Apr;59(4):992-995. doi: 10.1080/10428194.2017.1361029. Epub 2017 Aug 9. No abstract available.

PMID:
28792266
28.

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH.

Leukemia. 2018 Feb;32(2):303-312. doi: 10.1038/leu.2017.243. Epub 2017 Jul 28.

PMID:
28751770
29.

Marked leukemoid reaction in a patient with metastatic breast carcinoma.

Harvey Y, Bleakley S, Blombery P, Bain BJ.

Am J Hematol. 2018 Feb;93(2):306-307. doi: 10.1002/ajh.24849. Epub 2017 Jul 29. No abstract available.

30.

Primary Breast Lymphoma-Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma.

Blombery P, Prince HM, Seymour JF.

J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djx010. No abstract available.

PMID:
28376146
31.

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.

Yeh P, Hunter T, Sinha D, Ftouni S, Wallach E, Jiang D, Chan YC, Wong SQ, Silva MJ, Vedururu R, Doig K, Lam E, Arnau GM, Semple T, Wall M, Zivanovic A, Agarwal R, Petrone P, Jones K, Westerman D, Blombery P, Seymour JF, Papenfuss AT, Dawson MA, Tam CS, Dawson SJ.

Nat Commun. 2017 Mar 17;8:14756. doi: 10.1038/ncomms14756.

32.

Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.

Agarwal R, Blombery P, McBean M, Jones K, Fellowes A, Doig K, Forsyth C, Westerman DA.

Ann Hematol. 2017 May;96(5):725-732. doi: 10.1007/s00277-017-2937-6. Epub 2017 Feb 4.

PMID:
28161773
33.

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.

Yeh P, Dickinson M, Ftouni S, Hunter T, Sinha D, Wong SQ, Agarwal R, Vedururu R, Doig K, Fong CY, Blombery P, Westerman D, Dawson MA, Dawson SJ.

Blood. 2017 Mar 23;129(12):1685-1690. doi: 10.1182/blood-2016-09-740308. Epub 2017 Jan 26.

34.

Transformed Lymphoma.

Anderson MA, Blombery P, Seymour JF.

Hematol Oncol Clin North Am. 2016 Dec;30(6):1317-1332. doi: 10.1016/j.hoc.2016.07.012. Review.

PMID:
27888883
35.

Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement.

Chan KL, van der Weyden C, Khoo C, Lade S, Blombery P, Westerman D, Khot A, Melo B, Johnstone RW, Prince HM, Dickinson M.

Leuk Lymphoma. 2017 Apr;58(4):996-998. doi: 10.1080/10428194.2016.1222375. Epub 2016 Aug 25. No abstract available.

PMID:
27558082
36.

Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.

Blombery P, Thompson ER, Jones K, Arnau GM, Lade S, Markham JF, Li J, Deva A, Johnstone RW, Khot A, Prince HM, Westerman D.

Haematologica. 2016 Sep;101(9):e387-90. doi: 10.3324/haematol.2016.146118. Epub 2016 May 19. No abstract available.

37.

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.

Chan KL, Blombery P, Jones K, Lade S, Carney D, Tran H, Seymour JF, Tam CS.

Br J Haematol. 2017 Apr;177(2):324-328. doi: 10.1111/bjh.14062. Epub 2016 May 15. No abstract available.

PMID:
27196127
38.

Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.

Patriquin CJ, Thomas MR, Dutt T, McGuckin S, Blombery PA, Cranfield T, Westwood JP, Scully M.

Br J Haematol. 2016 Jun;173(5):779-85. doi: 10.1111/bjh.13993. Epub 2016 Mar 24.

PMID:
27009919
39.

Copper deficiency mimicking myelodysplastic syndrome.

Rady K, Westerman D, Blombery P, Turner P, Seymour J.

Leuk Lymphoma. 2016 May;57(5):1223-6. doi: 10.3109/10428194.2015.1086920. Epub 2015 Dec 23. No abstract available.

PMID:
26693885
40.

Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry.

Blombery P, Kivivali L, Pepperell D, McQuilten Z, Engelbrecht S, Polizzotto MN, Phillips LE, Wood E, Cohney S; TTP registry steering committee.

Intern Med J. 2016 Jan;46(1):71-9. doi: 10.1111/imj.12935.

PMID:
26477687
41.

The molecular pathogenesis of B-cell non-Hodgkin lymphoma.

Blombery PA, Wall M, Seymour JF.

Eur J Haematol. 2015 Oct;95(4):280-93. doi: 10.1111/ejh.12589. Epub 2015 Jun 9. Review.

PMID:
25996166
42.

The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.

Fleming S, Harrison SJ, Blombery P, Joyce T, Stokes K, Seymour JF, Prince HM, Ritchie D.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):291-6. doi: 10.1016/j.clml.2014.02.001. Epub 2014 Feb 15.

PMID:
24629850
43.

Management of thrombotic thrombocytopenic purpura: current perspectives.

Blombery P, Scully M.

J Blood Med. 2014 Feb 5;5:15-23. doi: 10.2147/JBM.S46458. eCollection 2014. Review.

44.

De novo B-cell prolymphocytic leukemia with central nervous system involvement.

Tatarczuch M, Blombery P, Seymour JF.

Leuk Lymphoma. 2014 Jul;55(7):1665-7. doi: 10.3109/10428194.2013.842991. Epub 2014 Apr 29. No abstract available.

PMID:
24047478
45.

Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations.

Blombery P, Kothari J, Yong K, Allen C, Gale RE, Khwaja A.

Leuk Lymphoma. 2014 Jul;55(7):1661-2. doi: 10.3109/10428194.2013.842990. Epub 2013 Nov 1. No abstract available.

PMID:
24033109
46.

An atypical presentation of persistent polyclonal B-lymphocytosis with symptomatic splenomegaly and response to rituximab.

Blombery P, Came N, Maxwell E, Herbert K.

Pathology. 2013 Jun;45(4):437-40. doi: 10.1097/PAT.0b013e328360f04f. No abstract available.

PMID:
23635822
47.

Molecular lesions in B-cell lymphoproliferative disorders: recent contributions from studies utilizing high-throughput sequencing techniques.

Blombery PA, Dickinson M, Westerman DA.

Leuk Lymphoma. 2014 Jan;55(1):19-30. doi: 10.3109/10428194.2013.792112. Epub 2013 May 9. Review.

PMID:
23550993
48.

Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.

Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, Reid CM, Golledge J, Kingwell BA.

JAMA. 2013 Feb 6;309(5):453-60. doi: 10.1001/jama.2012.216237. Retraction in: JAMA. 2015 Oct 13;314(14):1520-1.

PMID:
23385271
49.

Erdheim-Chester disease harboring the BRAF V600E mutation.

Blombery P, Wong SQ, Lade S, Prince HM.

J Clin Oncol. 2012 Nov 10;30(32):e331-2. doi: 10.1200/JCO.2012.43.2260. Epub 2012 Sep 24. No abstract available.

PMID:
23008323
50.

Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders.

Blombery PA, Wong SQ, Hewitt CA, Dobrovic A, Maxwell EL, Juneja S, Grigoriadis G, Westerman DA.

Haematologica. 2012 May;97(5):780-3. doi: 10.3324/haematol.2011.054874. Epub 2011 Dec 1.

Supplemental Content

Loading ...
Support Center